phase 2: what the trials say vs what this community says
phase 2: what the trials say vs what this community says — a position I have arrived at slowly and would like tested.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Kept a log specifically because there is so little published. It is one person and it is not data.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
How fast was the escalation? That is usually the variable that explains the reports.
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.